Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
San Raffaele University
Eikon Therapeutics
VA Office of Research and Development
Radiopharm Theranostics, Ltd
Replimune Inc.
Fudan University
St. Jude Children's Research Hospital
Novartis
University of Cincinnati
GlaxoSmithKline
Women's Hospital School Of Medicine Zhejiang University
UNICANCER
ImmunityBio, Inc.
Shanghai Zhongshan Hospital
Sun Yat-sen University
Massive Bio, Inc.
7 Hills Pharma, LLC
National Cancer Institute (NCI)
University of Pittsburgh
Medicenna Therapeutics, Inc.
AIO-Studien-gGmbH
GERCOR - Multidisciplinary Oncology Cooperative Group
Sanford Health
M.D. Anderson Cancer Center
WellSpan Health